Infant Bacterial Therapeutics AB (IBT) announced today that the U.S. Food and Drug Administration (FDA), has granted the company’s request for a...
2026-09-18 10:40
NOMINATION COMMITTEE FOR INFANT BACTERIAL THERAPEUTICS AB (PUBL) FOR THE ANNUAL GENERAL MEETING 2027
The Nomination Committee for Infant Bacterial Therapeutics AB for the Annual General Meeting 2027 has been appointed based on the ownership structure as...
Message from CEO During the period, work continued on building the scientific and medical positioning for bringing IBP-9414, the company’s drug candidate...
2026-07-07 12:05
Infant Bacterial Therapeutics CFO Leaves the Company
Infant Bacterial Therapeutics AB’s Chief Financial Officer (CFO), Maria Ekdahl, will leave IBT on October 7. IBT plans to use an external consultant...
2026-05-07 17:15
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 7, 2026, among other things, the following was resolved: - to adopt the...
Message from CEO Continued constructive dialogue with the FDADuring the period, we continued our interactions with the U.S. Food and Drug Administration...
On March 30, 2026, Infant Bacterial Therapeutics AB (publ) published a notice of the Annual General Meeting to be held on May 7, 2026. The following is...
2026-03-30 14:30
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
The Annual Report including Corporate Governance Report for 2025 is available on IBT´s website, www.ibtherapeutics.com under the section "Investors...
2026-03-03 07:00
Infant Bacterial Therapeutics (IBT) publishes results from ”The Connection Study” in Pediatric Research
IBT is pleased to announce that results from its pivotal Phase III trial, with IBP-9414 in very low birth weight infants “The Connection Study&rdquo...